抗Jo-1抗体综合征研究进展  

Research progress in anti-Jo-1 syndrome

作　　者：余雯文 吴立琴[1] 戴元荣[1] Yu Wenwen;Wu Liqin;Dai Yuanrong(Department of Respiratory and Critical Care Medicine,the Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325027,China)

机构地区：[1]温州医科大学附属第二医院呼吸与危重症医学科,325027

出　　处：《国际呼吸杂志》2019年第21期1670-1674,共5页International Journal of Respiration

摘　　要：抗Jo-1抗体综合征又称抗组氨酰-tRNA合成酶综合征,是一种因自身肌炎特异性抗体功能紊乱而出现的临床症候群,可累及肺部、肌肉、关节等全身多脏器.抗Jo-1抗体综合征中70%~90%的患者伴间质性肺疾病,该病误诊率高,治疗效果不佳,易复发,5年生存率不足70%.为了提高对本病的认识,减少误诊和漏诊,本文就抗Jo-1抗体综合征的诊治进展作一综述.Anti-Jo-1 syndrome,known as anti-hystroyl-tRNA synthetase syndrome,is a clinical syndrome caused by dysfunction of specific antibodies against automyositis,which involves multiple organs such as lungs,muscles and joints.70%to 90%of anti-Jo-1 syndrome patients have interstitial lung disease.Anti-Jo-1 syndrome has high misdiagnosis rate,poor treatment effect,easy recurrence,and the five-year survival rate is less than 70%.In order to improve the understanding of anti-Jo-1 syndrome,reduce misdiagnosis and missed diagnosis,the progress of diagnosis and treatment of anti-Jo-1 syndrome is summarized as follows.

关 键 词：抗Jo-1抗体综合征 肺疾病 间质性 发病机制 诊治 

分 类 号：R73[医药卫生—肿瘤]